________________________ |
________________________________________________________________________________________________ |
________________________________________________________________________________________________ |
________________________________________________________________________________________________ |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
________________________________________________________________________________________________ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Director Nominee | Votes For | Votes Against | Abstentions | ||||||||
Scott Biller, Ph.D. | 20,425,665 | 4,930,514 | 10,337 | ||||||||
Thomas J. Lynch, M.D. | 24,052,377 | 1,293,218 | 20,921 | ||||||||
Michael Mendelsohn, M.D. | 22,357,558 | 2,988,038 | 20,920 |
FOGHORN THERAPEUTICS INC. | |||||||||||
By: | /s/ Kristian Humer | ||||||||||
Kristian Humer | |||||||||||
Chief Financial Officer | |||||||||||
Cover |
Jun. 26, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Jun. 26, 2024 |
Entity Registrant Name | Foghorn Therapeutics Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39634 |
Entity Tax Identification Number | 47-5271393 |
Entity Address, Address Line One | 500 Technology Square, Ste 700 |
Entity Address, Postal Zip Code | 02139 |
City Area Code | 617 |
Local Phone Number | 586-3100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of each class | Common Stock, $0.0001 par value per share |
Trading Symbol(s) | FHTX |
Name of each exchange on which registered | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Amendment Flag | false |
Entity Central Index Key | 0001822462 |
Entity Address, City or Town | MA |
Entity Address, City or Town | Cambridge, |
^:ZLE3JBWMXC$>>[X@@A<@Z"8Z7%YA"FCHEY/AZ$/6JWW2!Q_>O
MZ@]EY[$S2VY@JM+/(K;)R!MX+(85+U+[K#;OX-"A$C!2J2D_V6;_;J?CL:@P
M5F6'8"3(A-Q?^?8P$,JA?0PY9%*=?0B@YAM_NP\(VPGPMYQ<+>!0O]L///\!82
M5!AAA1&6>FT*@_TY61JK,5%_-1'M%3K-"F[VWIB<1S#R<'H:T"_@C;_[)NCY
M/Q)\[8JO3:F/[U14X%RT;+'+H0F.#A]RHY_U=3_ 102P,$% @ B8#:6)>*NQS $P(
M L !?